Symbols

DAWN

Day One·NASDAQ

--(--)

DAWN fundamentals

DAWN Q4 2025 Earnings

Day One (DAWN) released its earnings on Feb 24, 2026: revenue was 53.71M (YoY +83.95%), beat estimates; EPS was -0.21 (YoY +66.67%), missed estimates.

Revenue / YoY

53.71M

+83.95%

EPS / YoY

-0.21

+66.67%

Report date

Feb 24, 2026

DAWN Earnings Call Summary for Q4,2025

OJEMDA Dominance: 172% YoY revenue growth ($155.4M in 2025) and 180% prescription growth highlight OJEMDA's rapid adoption in pLGG.
3-Year Data Strength: 53% ORR and 19.4-month median response duration validate OJEMDA's durability and safety, positioning it for front-line trials.
Pipeline Expansion: Emi-Le (ACC) shows promise for accelerated approval, while DAY301 advances in PTK7-expressing cancers.
Financial Fortitude: $441M cash position and scalable model support 2026 guidance of $225-250M OJEMDA revenue.

Earnings

EPS

Revenue

Revenue & Expenses

DAWN has released its 2025 Q4 earnings report, with revenue of 53.72M, reflecting a YoY change of 83.92%, and net profit of -21.28M, showing a YoY change of 67.62%. The Sankey diagram below clearly presents DAWN's revenue sources and cost distribution.

Key Indicators

Day One (DAWN) key financial stats and ratios, covering profitability, financial health, and leverage.

Income Statement

Day One (DAWN)'s revenue and profit trends over recent years, visualized with a waterfall chart to showcase the revenue-to-profit funnel.

Trend

Breakdown

Balance Sheet

Day One (DAWN)'s asset and liability trends over recent years, visualized with a waterfall chart to illustrate changes in its asset-liability structure.

Trend

Breakdown

Cash Flow

Day One (DAWN)'s cash flow trends over recent years, visualized with a waterfall chart to illustrate changes in its operating, investing, and financing cash flows.

Trend

Breakdown